Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. D. Rothmann
U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis
Clinical Cancer Research
Cancer Research
Oncology
Related publications
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Clinical Cancer Research
Cancer Research
Oncology
Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma
Oncologist
Cancer Research
Medicine
Oncology
Transparency and Dermatologic Device Approval by the US Food and Drug Administration
JAMA Dermatology
Dermatology
Medicine
Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis
Blood Cancer Journal
Oncology
Hematology
Inclusion of Training Patients in US Food and Drug Administration Premarket Approval Cardiovascular Device Studies
Archives of Internal Medicine
Ruxolitinib as an Emerging Treatment in Myelofibrosis
Blood and Lymphatic Cancer: Targets and Therapy
Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly
British Journal of Haematology
Hematology
Efficacy of Ruxolitinib for Myelofibrosis
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
